Tormere Analytics
OverviewStock ResearchChartsPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Articles
Pricing
Privacy PolicyTerms of Service

DMRA

$20.46-0.97%website ↗⬇ financials (.py)

Damora Therapeutics, Inc.

Market Cap
$1.3B
Live price × shares (2026-09-16)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
1.44
60mo monthly vs SPY
P/E (TTM)
N/M
Price / TTM net income
P/S (TTM)
—
Price / TTM revenue
P/B
2.4
Price / stockholders equity
EV/EBITDA
—
TTM
Price Chart
Loading…

Signals

Insider Velocity
24.0x
selling
Congress
—
recent trades
Short Volume
42%
W/W -14.8pp

Market & Alt Data

News
15
recent articles
Activist
13D
Fairmount
Analyst Consensus
Strong Buy
16 analysts
Velocity Score
23.98x
Sell Rate (90d)
2.72/mo
Sell Baseline
0.00/mo
Unique Sellers (90d)
1
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-07-062026-07-07Winslow GarrettGeneral CounselSale245$29.98$7K2,289View

Recent News

(DMRA) Movement Within Algorithmic Entry Frameworks
Stock Traders Daily · 2026-09-27
DMRA Maintained by Guggenheim -- Price Target Raised to $60.00
GuruFocus · 2026-09-25
Guggenheim maintains Buy rating on Damora Therapeutics, $60 price target
TradingView · 2026-09-25
Guggenheim raises Damora Therapeutics price target on MF sales outlook
Investing.com · 2026-09-25
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60
Benzinga · 2026-09-25
$DMRA stock is down 14% today. Here's what we see in our data.
Quiver Quantitative · 2026-09-15
Damora Therapeutics: Potential Payday Is A Long Way Off
SeekingAlpha · 2026-09-15
Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA)
Seeking Alpha · 2026-09-15
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo · 2026-09-03
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Yahoo Finance · 2026-08-10
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Yahoo Finance · 2026-08-05
Damora Announces Redomestication from Delaware to Cayman Islands
Yahoo Finance · 2026-07-17
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
Yahoo Finance · 2026-05-30
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Yahoo Finance · 2026-05-12
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
Yahoo Finance · 2026-05-08

Informational purposes only, not investment advice.

Damora Therapeutics, Inc. (DMRA)

tormere.com/research/DMRA · generated 2026-09-28

$20.46
-0.97%
General Information
Price$20.46
Change-0.97%
Market Cap$1.3B
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, 60mo vs SPY)1.44
Signals
Insider Velocity24.0x selling
Congress Trades—
Short Volume
42% of daily vol
Conviction Score21/100
Analyst ConsensusSB 6 · B 9 · H 1 · S 0 · SS 0
Price Chart (1 Year)
2025-09-292026-09-25$34.14$3.52
Recent Insider Activity (Form 4) — Last 5
DateInsiderTypeSharesValue
2026-07-06Winslow GarrettS245$7,345.1
Recent News
  • (DMRA) Movement Within Algorithmic Entry Frameworks — Stock Traders Daily · 2026-09-27
  • DMRA Maintained by Guggenheim -- Price Target Raised to $60.00 — GuruFocus · 2026-09-25
  • Guggenheim maintains Buy rating on Damora Therapeutics, $60 price target — TradingView · 2026-09-25
  • Guggenheim raises Damora Therapeutics price target on MF sales outlook — Investing.com · 2026-09-25
  • Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60 — Benzinga · 2026-09-25

Tormere — informational purposes only, not investment advice.

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →